Search PubMed⌕ Search

Biomedical subjects

J Hildebrand

Publications and source records attributed to J Hildebrand.

At least 145 records · Page 8Linked to original sources
PubMed1971

Neutral glycolipids in leukemic and nonleukemic leukocytes.

Neutral lipids, free and total cholesterol, glycolipids, and phospholipids were determined in 20 preparations of leukocytes distributed in four groups. Group I consisted of leukocytes from nonleukemic patients; group II, from patients with chronic myelogenous leukemia; group III, from patients with chronic lymphocytic leukemia; and group IV, from patients with acute leukemia. Two neutral glycolipids were found in nonleukemic mixed leukocyte populations. They were identified as glucosylceramide and lactosylceramide. The same glycolipids were also present in leukemic cells, but striking differences in glycolipid composition were found in various types of leukocytes. Glycolipids accounted for 8.9-12.6% of the total lipids in leukocytes from group I, 11.4-20.4% in group II, 1.2-1.6% in group III, and 0.5-4.9% in group IV. Glucosylceramide was the only glycolipid found in seven out of eight analyzed samples of lymphocytes, both normal and leukemic. Lactosylceramide was the major glycolipid in preparations consisting mainly of polymorphonuclear, myeloid, and blastic cells. Only lactosylceramide was found in platelets, where its concentration was about 100 times lower than in mixed leukocyte populations.

Blood Cell Count↗
PubMedDate not supplied

Prophylaxis and treatment of leptomeningeal carcinomatosis in solid tumors of adulthood.

Despite the lack of randomized and prospective studies the benefit of MC therapy can not be attributed merely to patient selection, since substantial increase of survival time and long term survivors are seen only in patients who have received, and responded to treatment. In the absence of factors predicting the therapeutic response, all patients with overt MC should be treated with the possible exception of these with widespread and uncontrolled systemic neoplasia. The respective weight of systemic and intraventricular chemotherapy, and radiation therapy, remains unclear. It may depend upon the stage and the nature of the primary neoplasia. When intraventricular MTX is used, monitoring of drug concentrations is advised.

Adult↗